nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

23.12.2023 | Editorial

Alpha emitter isotopes and PSMA ligands: the near future therapeutic prospective for castration-resistant prostate cancer

verfasst von: Fabio Volpe, Leandra Piscopo, Emilia Zampella, Michele Klain

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Excerpt

The theragnostic approach was proposed with the introduction of 131-Iodine for the treatment of both benign and malign thyroid diseases [1‐5]. The therapeutic effect of 131-Iodine is based on its ability to emit -particles, which are characterized by a high linear energy transfer (LET) and a relatively long range of penetration. The β-emission increases the average dose to the tumor, but it also results in irradiation of surrounding healthy tissue [1‐6]. During the last years, [¹⁷⁷Lu]Lu-PSMA-617 has been introduced as a promising and effective therapy in patients with prostate cancer and metastatic disease [7‐9]. Similarly, to 131-Iodine, ¹⁷⁷Lu is a typical theragnostic agent, able to emit both β-particles and γ photons. The use of [¹⁷⁷Lu]Lu-PSMA-617 has been previously tested in several populations with metastatic castration-resistant prostate cancer (mCRPC). VISION study [7], an important multicenter phase 3 randomized trial of 831 mCRPC patients, demonstrated that [¹⁷⁷Lu]Lu-PSMA-617 plus standard of care (SOC) significantly prolonged radiological progression-free survival (rPFS) (8.7 vs. 3.4, months) and overall survival (OS) (15.3 vs. 11.3, months) compared to control group of SOC patients. In addition, the quality of life was not adversely affected by this innovative and revolutionary therapy. …

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. https://doi.org/10.1089/thy.2015.0020.CrossRefPubMedPubMedCentral

Klain M, Pace L, Zampella E, Mannarino T, Limone S, Mazziotti E, et al. Outcome of patients with differentiated thyroid cancer treated with 131-Iodine on the basis of a detectable serum thyroglobulin level after initial treatment. Front Endocrinol (Lausanne). 2019;10:146. https://doi.org/10.3389/fendo.2019.00146.CrossRefPubMed

Klain M, Zampella E, Manganelli M, Gaudieri V, Nappi C, D’Antonio A, et al. Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancer. Endocrine. 2021;71(2):378–84. https://doi.org/10.1007/s12020-020-02379-1.CrossRefPubMed

Nappi C, Klain M, Cantoni V, Green R, Piscopo L, Volpe F, et al. Risk of primary breast cancer in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2022;49(5):1630–9. https://doi.org/10.1007/s00259-021-05625-4.CrossRefPubMed

Klain M, Maurea S, Gaudieri V, Zampella E, Volpe F, Manganelli M, et al. The diagnostic role of total-body 18F-FDG PET/CT in patients with multiple tumors: a report of the association of thyroid cancer with lung or renal tumors. Quant Imaging Med Surg. 2021;11(9):4211–5. https://doi.org/10.21037/qims-21-36.CrossRefPubMedPubMedCentral

Klain M, Nappi C, De Risi M, Piscopo L, Volpe F, Manganelli M, et al. Whole-body radioiodine effective half-life in patients with differentiated thyroid cancer. Diagnostics (Basel). 2021;11(10):1740. https://doi.org/10.3390/diagnostics11101740.CrossRefPubMed

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103. https://doi.org/10.1056/NEJMoa2107322.CrossRefPubMedPubMedCentral

Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. TheraP trial investigators and the Australian and New Zealand urogenital and prostate cancer trials group. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804.CrossRefPubMed

Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46(12):2536–44. https://doi.org/10.1007/s00259-019-04485-3.CrossRefPubMed

10.

Klain M, Gaudieri V, Petretta M, Zampella E, Storto G, Nappi C, et al. Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer. Future Sci OA. 2021;7(8):FSO719. https://doi.org/10.2144/fsoa-2021-0053.CrossRefPubMedPubMedCentral

11.

Kratochwil C, Haberkorn U, Giesel FL. Radionuclide therapy of metastatic prostate cancer. Semin Nucl Med. 2019;49(4):313–25. https://doi.org/10.1053/j.semnuclmed.2019.02.003.CrossRefPubMed

12.

Kang J, La Manna F, Bonollo F, Sampson N, Alberts IL, Mingels C, Afshar-Oromieh A, Thalmann GN, Karkampouna S. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Lett. 2022;530:156–69. https://doi.org/10.1016/j.canlet.2022.01.015.CrossRefPubMed

13.

Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with 225Actinium and 213Bismuth. Curr Radiopharm. 2018;11(3):200–8. https://doi.org/10.2174/1874471011666180502104524.CrossRefPubMedPubMedCentral

14.

Dhiman D, Vatsa R, Sood A. Challenges and opportunities in developing Actinium-225 radiopharmaceuticals. Nucl Med Commun. 2022;43(9):970–7. https://doi.org/10.1097/MNM.0000000000001594.CrossRefPubMed

15.

Dhiantravan N, Hofman MS, Ravi Kumar AS. Actinium-225 prostate-specific membrane antigen theranostics: will α beat β? Eur Urol. 2021;79(3):351–2. https://doi.org/10.1016/j.eururo.2020.12.011.CrossRefPubMed

16.

Satapathy S, Chandekar KR, Bal C. Gastro-enteric-pancreatic neuroendocrine tumor treatment: Actinium-225-DOTATATE and combined therapies. PET Clin. 2023;18(2):215–21. https://doi.org/10.1016/j.cpet.2022.11.004.CrossRefPubMed

17.

Królicki L, Kunikowska J, Bruchertseifer F, Koziara H, Królicki B, Jakuciński, et al. 225Ac- and 213Bi-substance P analogues for glioma therapy. Semin Nucl Med. 2020;50(2):141–51. https://doi.org/10.1053/j.semnuclmed.2019.11.004.CrossRefPubMed

18.

Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, et al. Activity and adverse events of Actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of Lutetium-177-PSMA. Eur Urol. 2021;79(3):343–50. https://doi.org/10.1016/j.eururo.2020.11.013.CrossRefPubMed

19.

Ballal S, Yadav MP, Satapathy S, Raju S, Tripathi M, Damle NA, et al. Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study. Eur J Nucl Med Mol Imaging. 2023;50(12):3777–89. https://doi.org/10.1007/s00259-023-06340-y.CrossRefPubMed

20.

Groener D, Schneider S, Baumgarten J, Happel C, Klimek K, Mader N, et al. Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 radioligand therapy: value of PSMA-uptake thresholds in predicting targetable lesions. Cancers (Basel). 2023;15(2):473. https://doi.org/10.3390/cancers15020473.CrossRefPubMed

21.

Volpe F, Nappi C, Piscopo L, Zampella E, Mainolfi CG, Ponsiglione A, et al. Emerging role of nuclear medicine in prostate cancer: current state and future perspectives. Cancers (Basel). 2023;15(19):4746. https://doi.org/10.3390/cancers15194746.CrossRefPubMed

22.

Groener D, Wichert J, Adams M, Mader N, Klimek K, Nguyen Ngoc C, et al. Impact of [177Lu]Lu-PSMA-617 radioligand therapy on reference organ uptake assessed by [68Ga]Ga-PSMA-11-PET/CT. Cancers (Basel). 2023;15(15):3878. https://doi.org/10.3390/cancers15153878.CrossRefPubMed

Titel: Alpha emitter isotopes and PSMA ligands: the near future therapeutic prospective for castration-resistant prostate cancer
verfasst von: Fabio Volpe
Leandra Piscopo
Emilia Zampella
Michele Klain
Publikationsdatum: 23.12.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2024
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-023-06574-w

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Alpha emitter isotopes and PSMA ligands: the near future therapeutic prospective for castration-resistant prostate cancer

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2024

The EANM Focus 5 consensus on ‘molecular imaging and theranostics in prostate cancer’: the future begins today

Performance of [18F]fluorocholine PET/CT in MEN1-related primary hyperparathyroidism before initial surgery or for persistent/recurrent disease

[177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models

Adhesion molecule–targeted magnetic particle imaging nanoprobe for visualization of inflammation in acute lung injury

Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy

Beyond stillness: the importance of tackling patient’s motion for reliable parametric imaging